These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 11275975)

  • 21. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
    Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
    Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
    Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
    Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.
    Baxevanis CN; Voutsas IF; Tsitsilonis OE; Gritzapis AD; Sotiriadou R; Papamichail M
    J Immunol; 2000 Apr; 164(7):3902-12. PubMed ID: 10725753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
    Meijer SL; Dols A; Urba WJ; Hu HM; Smith II JW; Vetto J; Wood W; Doran T; Chu Y; Sayaharuban P; Alvord WG; Fox BA
    J Immunother; 2002; 25(4):359-72. PubMed ID: 12142559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation.
    Kurokawa T; Fischer K; Bertz H; Hoegerle S; Finke J; Mackensen A
    Int J Cancer; 2002 Sep; 101(1):52-60. PubMed ID: 12209588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ex vivo expansion of antitumor cytotoxic lymphocytes with tumor-associated antigen-loaded dendritic cells.
    Gervais A; Bouet-Toussaint F; Toutirais O; De La Pintiere CT; Genetet N; Catros-Quemener V
    Anticancer Res; 2005; 25(3B):2177-85. PubMed ID: 16158961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
    Ramadan G
    Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.
    Santin AD; Bellone S; Ravaggi A; Pecorelli S; Cannon MJ; Parham GP
    Obstet Gynecol; 2000 Sep; 96(3):422-30. PubMed ID: 10960637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling.
    Montagna D; Schiavo R; Gibelli N; Pedrazzoli P; Tonelli R; Pagani S; Assirelli E; Locatelli F; Pession A; Fregoni V; Montini E; Da Prada GA; Siena S; Maccario R
    Int J Cancer; 2004 May; 110(1):76-86. PubMed ID: 15054871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer.
    Santin AD; Bellone S; Palmieri M; Bossini B; Cane' S; Bignotti E; Roman JJ; Cannon MJ; Pecorelli S
    Int J Gynecol Cancer; 2004; 14(1):64-75. PubMed ID: 14764031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
    Itoh K; Platsoucas CD; Balch CM
    J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones.
    Bernhard H; Karbach J; Wölfel T; Busch P; Störkel S; Stöckle M; Wölfel C; Seliger B; Huber C; Meyer zum Büschenfelde KH
    Int J Cancer; 1994 Dec; 59(6):837-42. PubMed ID: 7989126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
    Stober D; Jomantaite I; Schirmbeck R; Reimann J
    J Immunol; 2003 Mar; 170(5):2540-8. PubMed ID: 12594280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergy between interleukin-2 and prothymosin alpha for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas.
    Voutsas IF; Baxevanis CN; Gritzapis AD; Missitzis I; Stathopoulos GP; Archodakis G; Banis C; Voelter W; Papamichail M
    Cancer Immunol Immunother; 2000 Oct; 49(8):449-58. PubMed ID: 11043852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
    Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
    Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
    Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
    Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigen presentation and immune regulatory capacity of immature and mature-enriched antigen presenting (dendritic) cells derived from human bone marrow.
    Jin Y; Fuller L; Ciancio G; Burke GW; Tzakis AG; Ricordi C; Miller J; Esquenzai V
    Hum Immunol; 2004 Feb; 65(2):93-103. PubMed ID: 14969764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells.
    Osterroth F; Garbe A; Fisch P; Veelken H
    Blood; 2000 Feb; 95(4):1342-9. PubMed ID: 10666209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.